Physician profile
Fredric N Herskowitz
NPI 1144260340
$1,173.99
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $180 · 2021: $241.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $281.55 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.62 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $91.60 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $81.34 | 2019-2021 | |
| Advanced Respiratory, INC | $63.16 | 2019-2021 | |
| Grifols USA, LLC | $48.20 | 2019 | |
| Circassia INC. | $44.19 | 2019 | |
| Insmed, INC. | $39.72 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $38.31 | 2019 | |
| Resmed Corp | $35.03 | 2019 | |
| Pfizer INC. | $32.01 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $29.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.40 | 2020 | |
| Veran Medical Technologies, INC. | $18.61 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $17.59 | 2019 | |
| Ambu INC. | $17.45 | 2020 | |
| Genzyme Corporation | $17.13 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.52 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredric Herskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.